Department of Critical Care Medicine, St. Joseph's University Medical Center, Paterson, NJ, USA.
First Department of Neurology, Eginition University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
J Intensive Care Med. 2023 Oct;38(10):922-930. doi: 10.1177/08850666231173847. Epub 2023 May 7.
To evaluate the association of etomidate with postintubation hypotension, inflammation, and mortality in critically ill patients with COVID-19.
International, multicenter, retrospective study.
Critically ill patients hospitalized specifically for COVID-19 from three major academic institutions in the US and Europe.
Patients were allocated into the etomidate (ET) group or another induction agent (OA) group. The primary outcome was postintubation hypotension. Secondary outcomes included postintubation inflammatory status, in-hospital mortality, and mortality at 30 days.
171 patients with a median age of 68 (IQR 58-73) years were included (ET, n = 98; OA, n = 73). Etomidate was associated with lower postintubation mean arterial pressure [74.33 (64-85) mm Hg 81.84 (69.75-94.25) mm Hg, p = 0.005] compared to other agents. No statistically significant differences were generally observed in inflammatory markers between the two groups at 7- and 14-days after admission to the intensive care unit. In-hospital mortality [77 (79%) 41 (56%), p = 0.003] and mortality at 30-days [78 (80%) 43 (59%), p = 0.006] were higher in the ET group. In multivariate logistic regression analysis, only etomidate (p = 0.009) and postintubation mean arterial pressure (p < 0.001) had a statistically significant effect on mortality, in contrast to stress-dose steroids (p = 0.301), after adjusting for creatinine (p = 0.695), blood urea nitrogen (p = 0.153), age (p = 0.055), oxygen saturation of hemoglobin (SpO) (p = 0.941), and fraction of inspired oxygen (FiO) (p = 0.712).
Administration of a single-bolus dose of etomidate in critically ill patients with COVID-19 is associated with lower postintubation mean arterial pressure and higher in-hospital and 30-day mortality compared to other induction agents.
评估依托咪酯与 COVID-19 危重症患者插管后低血压、炎症和死亡率的关系。
国际多中心回顾性研究。
来自美国和欧洲三家主要学术机构的 COVID-19 住院患者。
患者分为依托咪酯(ET)组或其他诱导剂(OA)组。主要结局为插管后低血压。次要结局包括插管后炎症状态、院内死亡率和 30 天死亡率。
共纳入 171 例中位年龄为 68(IQR 58-73)岁的患者(ET 组 98 例,OA 组 73 例)。与其他药物相比,依托咪酯与较低的插管后平均动脉压[74.33(64-85)mmHg比 81.84(69.75-94.25)mmHg,p=0.005]相关。在入住重症监护病房后的 7 天和 14 天,两组间的炎症标志物一般无统计学显著差异。院内死亡率[77(79%)比 41(56%),p=0.003]和 30 天死亡率[78(80%)比 43(59%),p=0.006]在 ET 组更高。多变量逻辑回归分析显示,仅依托咪酯(p=0.009)和插管后平均动脉压(p<0.001)对死亡率有统计学显著影响,而应激剂量类固醇(p=0.301)、肌酐(p=0.695)、血尿素氮(p=0.153)、年龄(p=0.055)、血红蛋白氧饱和度(SpO)(p=0.941)和吸入氧分数(FiO)(p=0.712)在调整后无统计学显著影响。
与其他诱导剂相比,COVID-19 危重症患者单次推注依托咪酯与较低的插管后平均动脉压和更高的院内及 30 天死亡率相关。